Marshall Wace North America’s Xeris Biopharma Holdings XERS Stock Holding History

Marshall Wace North America’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-22,871	Closed	-$161K	–	1644
2019 Q4	$161K	Buy	+22,871	New	+$189K	﹤0.01%	1008
2019 Q2	–	Sell	-7,087	Closed	-$71K	–	1672
2019 Q1	$71K	Buy	+7,087	New	+$90.8K	﹤0.01%	1193
2018 Q3	–	Sell	-41,266	Closed	-$783K	–	1416
2018 Q2	$783K	Buy	+41,266	New	+$802K	﹤0.01%	996

Other funds holding XERS

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Hound Partners New York $863M AUM 11.22% 1-Year Est. Return

AGM

Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return

Marshall Wace North America's XERS Position: Q1 2020 in Review

Marshall Wace North America sold out of Xeris Biopharma Holdings (XERS) in Q1 2020, closing a stake of 22,871 shares — an estimated $161K sold.

Marshall Wace North America first reported a position in XERS in Q2 2018 and held it in 3 quarters. The position peaked at $783K in Q2 2018. 67 funds tracked by Wall St. Rank hold XERS as of Q1 2020.

Marshall Wace North America reported no remaining Xeris Biopharma Holdings position as of Q1 2020 after selling out during the quarter.
Marshall Wace North America sold 22,871 Xeris Biopharma Holdings shares in Q1 2020, an estimated $161K.
Marshall Wace North America first reported a position in Xeris Biopharma Holdings in Q2 2018 and held it in 3 quarters.
Marshall Wace North America's Xeris Biopharma Holdings position peaked at $783K in Q2 2018.
67 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2020.

Based on Marshall Wace North America's 13F filing for Q1 2020, filed 15 May 2020.